Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

• Status: Completed
• Trial end date: 2019-12-06
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients with gastrointestinal signs of GVHD that were treated with teduglutide.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Freiburg
• Treatments: Teduglutide

Criteria

Inclusion Criteria:

• Patients with signs of acute SR-GI-GVHD

• Age ≥ 18 years

• Peripheral blood and stool samples available before and during treatment

• Written informed consent

• Ability to understand the nature of the study and the study related procedures and to comply with them

Exclusion Criteria:

• Age ≤ 18 years

• Lack of informed consent